Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on February 28, 2019. The report covers events occurring on that date regarding the company's clinical development programs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance.
Material Changes
On February 28, 2019, the Company announced that two abstracts highlighting data from its lead clinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting (March 29 - April 3, 2019, in Atlanta, GA). The programs involve:
- Onvansertib in Acute Myeloid Leukemia (AML).
- Onvansertib in metastatic Castration-Resistant Prostate Cancer (mCRPC).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of clinical trial data presentation. The primary event is the acceptance of abstracts for presentation.
Investor Verification Checklist
- Verify the full content of the press release attached as Exhibit 99.1 for specific clinical data details.
- Confirm the presentation schedule and session details at the AACR Annual Meeting.
- Review subsequent filings for any updates on the clinical trial results presented.